

## Addendum

**Addendum: Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer**

**Tara Williamson<sup>1</sup>, Michelle Carvalho de Abreu<sup>1,2</sup>, Dimitri G. Trembath<sup>3</sup>, Cory Brayton<sup>4</sup>, Byunghak Kang<sup>4</sup>, Thais Biude Mendes<sup>1,5</sup>, Paulo Pimentel de Assumpção<sup>2</sup>, Janete M. Cerutti<sup>5</sup> and Gregory J. Riggins<sup>1</sup>**

<sup>1</sup>Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, USA

<sup>2</sup>Oncology Research Center, Federal University of Pará, Belém, Brazil

<sup>3</sup>Department of Pathology and Laboratory Medicine, University of North Carolina Hospitals, Women and Children Hospital, Chapel Hill, NC, USA

<sup>4</sup>Department of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, MD, USA

<sup>5</sup>Genetic Basis of Thyroid Tumors Laboratory, Division of Genetics, Universidade Federal de São Paulo, São Paulo, Brazil

**Published:**

**Copyright:** © 2023 Williamson et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has an addendum:** No funding was used for this publication.

Original article: Oncotarget. 2021; 12:1326–1338. <https://doi.org/10.18632/oncotarget.28014>